crispr
US scientists carry out first editing of human embryos
July 28, 2017Medical Communications, Research and Development biotech, crispr, drugs, gene editing, gene-editing, pharma, pharmaceutical
In what will be regarded as a watershed moment, scientists working at Oregon Health and Science University have used CRISPR …
Gene-editing tool CRISPR found to cause unintentional mutations in live animal models
May 30, 2017Manufacturing and Production, Research and Development crispr
Gene-editing has been heralded as a wonder tool which could lead to huge advances in a wide range of treatment …
The March 2017 issue of Pharmafocus is now live!
February 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo
The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …
US panel endorses human embryo gene editing, with caveats
February 15, 2017Research and Development crispr, gene editing
Gene editing in human embryos has been given the go-ahead by a panel of experts from the US National Academy …
China conducts first gene-editing human trial
November 21, 2016Research and Development, Sales and Marketing China, DNA, cas9, crispr
China has used Crispr/Cas9 gene-editing technology to edit the DNA of a human subject, suffering from metastatic lung cancer. This …
Horizon and Fulcrum Therapeutics form CRISPR collaboration
September 6, 2016Manufacturing and Production, Research and Development Horizon Discovery, crispr, fulcrum, fulcrum therapeutics, gene editing, horizon, rare diseases
Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to utilise Horizon’s CRISPR-based screening platform …
Bayer’s CRISPR venture opens for business in biotech hub
August 23, 2016Manufacturing and Production, Research and Development Bayer, casebia, crispr, gene editing, gene-editing
Bayer and CRISPR Therapeutics have joined together to launch Casebia Therapeutics and have chosen Cambridge, Massachusetts, as its base to …
Federal panel to review proposal for first human CRISPR test
June 20, 2016Research and Development, Sales and Marketing crispr, gene editing, human testing, oncology
A US Federal safety board is set to review a proposal for the first human use of the gene editing …
Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology
April 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics
Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …
HIV successfully overcomes CRISPR gene-editing technology
April 8, 2016Research and Development HIV, crispr, failure, setback
Researchers using the CRISPR gene-editing technology have indicated that HIV can defeat efforts to cripple it, but have characterised it …
AstraZeneca dives into gene editing
January 29, 2015Research and Development, Sales and Marketing AstraZeneca, Intellia Therapetics, Novartis, Thermo Fisher Scientific, Wellcome Trust Sanger Institute in Cambridge, Whitehead, broad institute, crispr, the Innovative Genomics Initiative in California
AstraZeneca is looking to harness the power of a pioneering genome-editing tool in a series of new collaborations. The UK …
UK to launch DNA database
November 8, 2013Sales and Marketing DNA, UK, crispr, genome
Volunteers prepared to share their DNA with the rest of the world are being sought by scientists in the UK, …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
